Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Sichuan Baili Pharmaceutical Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors

Phase 1

Recruiting

Conditions: Small Cell Lung Cancer
Neuroendocrine Tumors

Interventions: Drug: BL-M14D1

First Posted Date: 2024-07-17

Last Posted Date: 2024-08-14

Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Target Recruit Count: 22

Registration Number: NCT06505824

Locations: 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China

A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors

Phase 1

Recruiting

Conditions: Breast Cancer
Solid Tumor

Interventions: Drug: BL-M17D1

First Posted Date: 2024-07-16

Last Posted Date: 2024-11-12

Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Target Recruit Count: 20

Registration Number: NCT06503783

Locations: 🇨🇳
Harbin Medical University Cancer Hospital, Ha'erbin, Heilongjiang, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer

Phase 3

Recruiting

Conditions: Small Cell Lung Cancer

Interventions: Drug: BL-B01D1
Drug: Topotecan

First Posted Date: 2024-07-15

Last Posted Date: 2025-05-02

Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Target Recruit Count: 714

Registration Number: NCT06500026

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors

Phase 1

Recruiting

Conditions: Esophageal Cancer
Gastric Cancer
Pancreatic Cancer
Colorectal Cancer
Solid Tumor

Interventions: Drug: BL-M17D1

First Posted Date: 2024-07-15

Last Posted Date: 2024-08-22

Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Target Recruit Count: 20

Registration Number: NCT06500052

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Phase 2

Recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: BL-B01D1
Drug: Osimertinib Mesylate Tablets

First Posted Date: 2024-07-12

Last Posted Date: 2025-05-07

Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Target Recruit Count: 40

Registration Number: NCT06498986

Locations: 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China

A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors

Phase 1

Not yet recruiting

Conditions: Breast Cancer
Solid Tumor

Interventions: Drug: BL-B16D1

First Posted Date: 2024-07-10

Last Posted Date: 2024-08-07

Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Target Recruit Count: 21

Registration Number: NCT06493864

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Study of BL-B16D1 in Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumor

Interventions: Drug: BL-B16D1

First Posted Date: 2024-06-26

Last Posted Date: 2024-08-09

Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Target Recruit Count: 21

Registration Number: NCT06475131

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

Phase 2

Recruiting

Conditions: Nasopharyngeal Carcinoma
Non-small Cell Lung Cancer
Solid Tumor

Interventions: Drug: BL-B01D1
Drug: PD-1 Monoclonal Antibody

First Posted Date: 2024-06-26

Last Posted Date: 2025-05-07

Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Target Recruit Count: 332

Registration Number: NCT06475300

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer

Phase 2

Recruiting

Conditions: Triple-negative Breast Cancer

Interventions: Drug: BL-B01D1
Drug: PD-1 Monoclonal Antibody

First Posted Date: 2024-06-24

Last Posted Date: 2025-05-07

Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Target Recruit Count: 52

Registration Number: NCT06471205

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Study of BL-B16D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Phase 1

Recruiting

Conditions: Head and Neck Squamous Cell Carcinomas
Solid Tumor

Interventions: Drug: BL-B16D1

First Posted Date: 2024-06-21

Last Posted Date: 2024-08-07

Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Target Recruit Count: 21

Registration Number: NCT06469008

Locations: 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy